Table 1.
Characteristics of studies included in the analysis
| Author | Year | Type of study | Country | Duration | Treatment group medication | Number of patients in treatment group | Number of patients in the placebo group | Design | Blinding | Allocation coneealment (Yes/no) | Sample size calculations in manuscript (Yes/no) | ITT analysis (Yes/no) | Histologc scoring system used |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belfort | 2006 | Multi-center | USA | 6 months | Pioglitazone | 26 | 21 | RCT | None | No | Yes | Yes | Kleiner et al. |
| Dufour | 2006 | Multi-center | Switzerland | 24 months | Urso + Vit E; Urso alone | 15; 18 | 15 | RCT | Double-blind | No | No | No | Promrat et al. |
| Lindor | 2004 | Multi-center | North-America | 24 months | Urso | 80 | 86 | RCT | Double-blind | No | No | No | (Mod) Brunt et al. |
| Merat | 2003 | Single-center | Iran | 6 months | Probucol | 18 | 9 | RCT | Double-blind | No | No | No | Brunt et al. |
| Ratziu | 2008 | Multi-center | France | 12 months | Rosiglitazone | 32 | 31 | RCT | Double-blind | No | Yes | No | Brunt et al. Kleiner et al (NAS*only). |
Abbreviations: Urso, Ursodiol; Vit, Vitamin; RCT, randomized-controlled trial; NAS, NASH activity score